Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer

<i>Background</i>: Hormone receptor-positive and HER2-negative breast cancer (HR + BC) is the most prevalent breast cancer. Endocrine therapy is the mainstay of treatment, however, due to the heterogeneous nature of the disease, resistance to endocrine therapy is not uncommon. Over the past decades,...

Full description

Bibliographic Details

Main Authors:	Samitha Andrahennadi, Amer Sami, Mita Manna, Mehrnoosh Pauls, Shahid Ahmed
Format:	Artigo
Language:	Inglês
Published:	MDPI AG 2021-05-01
Series:	Current Oncology
Subjects:	breast cancer hormone receptor-positive breast cancer estrogen receptor-positive-breast cancer systemic therapy targeted therapy antiestrogen therapy
Online Access:	https://www.mdpi.com/1718-7729/28/3/168
Tags:	Add Tag No Tags, Be the first to tag this record!